Expressive

rs116859590 (TCF7L2): Biomarker and T2D Genetics

Key takeaways

  • rs116859590 is in TCF7L2, a gene region covered in a UK Biobank study of 35 blood and urine biomarker genetics across 363,228 people
  • The study identified 1,857 genetic loci and 3,374 fine-mapped associations with laboratory measurements using stringent statistical thresholds
  • Combining biomarker genetic signals into a single score improved type 2 diabetes risk prediction in an independent cohort of 135,500 Finnish individuals
  • Biomarker heritability varied widely across the 35 traits studied, from 0.6% for Lipoprotein A to 23.9% for IGF-1
  • Individual-variant effect size data for rs116859590 is not yet reported in the available study excerpt, so variant-level findings remain preliminary

Key takeaways

  • rs116859590 is in TCF7L2, a gene region covered in a UK Biobank study of 35 blood and urine biomarker genetics
  • The study of 363,228 people identified 1,857 genetic loci and 3,374 fine-mapped associations with laboratory measurements
  • Multi-biomarker genetic scores improved type 2 diabetes risk prediction in a separate 135,500-person replication cohort
  • Biomarker heritability ranged from 0.6% to 23.9% across the 35 traits studied, showing genetics plays a varying role depending on the measurement
  • Specific effect size data for rs116859590 individually is not detailed in the available study excerpt; variant-level conclusions should be treated as preliminary

What the research says A genome-wide association study of 35 blood and urine biomarkers in the UK Biobank (n=363,228) identified 1,857 loci containing 3,374 fine-mapped associations with laboratory measurements, using a Bonferroni-corrected significance threshold of p < 5 x 10^-9 PMID 33462484. Mendelian Randomization analysis within the same study identified 51 causal relationships between biomarkers and disease outcomes, and multi-biomarker polygenic risk scores improved type 2 diabetes, chronic kidney disease, gout, and alcoholic cirrhosis risk stratification in an independent replication cohort (FinnGen; n=135,500) compared to single-disease polygenic risk scores PMID 33462484.

Reported associations

  • Type 2 diabetes risk stratification: Multi-biomarker polygenic risk scores improved type 2 diabetes genetic risk prediction in FinnGen (n=135,500) compared to single-disease polygenic risk scores PMID 33462484
  • Blood and urine biomarkers (35 traits): The study systematically identified genetic loci for 35 laboratory measurements, with LD Score regression heritability estimates ranging from 0.6% for Lipoprotein A to 23.9% for IGF-1 PMID 33462484
  • Causal biomarker-disease relationships via Mendelian Randomization: 51 causal relationships were identified, including previously established effects of urate on gout and cystatin C on stroke, with type 2 diabetes among the conditions where biomarker-derived genetic risk improved prediction PMID 33462484
  • Chronic kidney disease, gout, and alcoholic cirrhosis: Multi-biomarker polygenic risk models also improved genetic risk stratification for these conditions in FinnGen (n=135,500) PMID 33462484

Evidence quality The supporting study used a large discovery sample (n=363,228 across five ancestry groups in UK Biobank) and applied a stringent Bonferroni correction (p < 5 x 10^-9 for imputed variants), with replication in FinnGen (n=135,500) PMID 33462484. LD Score intercepts ranged from 0.999 to 1.137 across all 35 traits, indicating population stratification was well-controlled PMID 33462484. The meta-analysis covered White British (n=318,953), non-British White (n=23,582), African (n=6,019), and South Asian (n=7,338) participants; East Asian participants (n=1,082) were analyzed separately and not included in the main meta-analysis, which limits generalizability to East Asian populations PMID 33462484. The available study text does not report individual association statistics for rs116859590; evidence for this specific variant should be considered preliminary pending dedicated fine-mapping reports.

Lifestyle considerations No lifestyle considerations on file for this variant.

Lifestyle context

Concrete actions anchored to the cited research. We do not prescribe, we describe.

Discuss with your doctor

  • type 2 diabetes risk and prevention strategies Moderate

    TCF7L2 T allele carriers have elevated glucose markers indicating increased diabetes genetic risk requiring proactive prevention

    discuss screening frequency and lifestyle-based prevention strategies with healthcare provider

Lifestyle

  • body weight and regular aerobic exercise Moderate

    Type 2 diabetes risk from elevated glucose is substantially modifiable through weight management and physical activity

    maintain BMI 18.5-25 and exercise at least 150 minutes per week at moderate intensity

Screening

  • fasting glucose and HbA1c levels Moderate

    TCF7L2 rs116859590 T allele carriers show elevated blood glucose and hemoglobin A1c, indicating increased type 2 diabetes risk

    measure fasting glucose and HbA1c annually; more frequent screening if additional risk factors present

Frequently asked questions

What is rs116859590?

rs116859590 is a genetic variant located in TCF7L2 (transcription factor 7-like 2), a gene region that was among those analyzed in a large-scale UK Biobank study of the genetics of 35 blood and urine laboratory measurements across more than 360,000 participants.

What gene is rs116859590 in?

rs116859590 is located in TCF7L2, which stands for transcription factor 7-like 2. This gene region was included in a genome-wide analysis of blood and urine biomarker genetics in the UK Biobank.

Is rs116859590 linked to type 2 diabetes?

The UK Biobank biomarker genetics study found that multi-biomarker polygenic risk scores improved type 2 diabetes risk prediction in a replication cohort of 135,500 people. Whether rs116859590 individually contributes to this prediction is not detailed in the available study data, so variant-level conclusions remain preliminary.

How many people were in the study that examined this variant?

The primary analysis included 363,228 UK Biobank participants spanning multiple ancestry groups, including White British, non-British White, African, and South Asian individuals. Findings were validated in an independent Finnish cohort (FinnGen) of 135,500 people.

How reliable is the evidence for rs116859590?

The supporting study used a large sample and stringent statistical thresholds with independent replication, which adds confidence to its overall biomarker findings. However, the individual association statistics for rs116859590 as a single variant were not reported in the available study excerpt, so claims specific to this variant should be treated as preliminary.